In summary, our study reveals that the IGFBP2/ITGA5 signaling pathway plays a crucial role in promoting resistance to gefitinib in NSCLC through the activation of STAT3/CXCL1 axis. Here, STAT3 is linked to non-small cell lung carcinoma.